Photo Credit: pexels.com
Cellulilte is one of those topics that most of us in the aesthetics space tend to be leery of. We’ve heard it all before; reduces dimples, pulverizes lumps and bumps, smooths skin, yada, yada, yada. These miracle cures often come with some discomfort, more downtime than expected, a longterm commitment to maintain the improvement, and a hefty price tag. Nonetheless, ‘cellulite’ continues to be a beauty buzzword that gets our attention because 80-90 percent of women, depending on who you ask, have it somewhere.
The long awaited first-ever cellulite injectable, called QWO from Endo Pharmaceuticals (collagenase clostridium histolyticum-aaes) now has FDA approval, and the data is
Photo Credit: facebook.com/Cellfina
Summer is quickly approaching, which means that getting rid of cellulite, the dimpled and lumpy cottage cheese skin that appears on our butts, thighs and abdomens, is a priority.
Fully 90 percent of women and 10 percent of men will develop cellulite, and despite the common perception, cellulite has little to do with weight. It can and does strike people of all sizes and ages. (Demi Lovato recently shared photos of her own cellulite on Instagram.)
We still aren’t totally sure what causes cellulite to develop, but hormones, genes and unhealthy lifestyles are certainly part of the story. The good news is that we are getting better and better at diminishing cellulite’s appearance, ex
The newest dimple destroyer has some interesting and unexpected roots.
Collagenase clostridium histolyticum (CCH) is being studied for its potential effects on releasing skin irregularities and thus, smoothing the skin. CCH is currently FDA-approved in the United States as XIAFLEX® for the treatment of adult Dupuytren’s contracture, which is a hand deformity that causes hard knots of tissue to form under the skin that result in fingers being pulled in a bent position, and also for men with Peyronie’s disease that can cause a curvature deformity in their male organ.
A Phase 2b study of CCH for treating cellulite will soon be underway, conducted by Endo International. The Phase 2b tri